Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,394 | 0,474 | 06.06. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
29.05. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES RECEIPT OF US$85MN FROM MERCK IN CONSIDERATION FOR PIMICOTINIB (ABSK021) GLOBAL ... | 10 | HKEx | ||
26.05. | China's CDE grants breakthrough status approval to Abbisko's HCC therapy | 1 | Pharmaceutical Technology | ||
ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
26.05. | Abbisko Therapeutics Secures Breakthrough Therapy Designation For Irpagratinib In HCC Treatment | 1 | RTTNews | ||
26.05. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - CDE APPROVAL OF BREAKTHROUGH THERAPY DESIGNATION FOR IRPAGRATINIB (ABSK011) OF ABBISKO THERAPEUTICS IN THE ... | 3 | HKEx | ||
23.05. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ORAL PRESENTATION BY ABBISKO THERAPEUTICS ON RESULTS OF PIMICOTINIB IN TGCT FROM THE PHASE 3 MANEUVER STUDY ... | 1 | HKEx | ||
22.05. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
20.05. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS' CSF-1R INHIBITOR, PIMICOTINIB (ABSK021), HAS BEEN GRANTED PRIORITY REVIEW FOR TGCT ... | 2 | HKEx | ||
16.05. | ABBISKO-B (02256): FORM OF PROXY FOR THE 2024 ANNUAL GENERAL MEETING | - | HKEx | ||
16.05. | ABBISKO-B (02256): NOTICE OF THE ANNUAL GENERAL MEETING | 1 | HKEx | ||
16.05. | ABBISKO-B (02256): PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND TO REPURCHASE SHARES RE-ELECTION OF DIRECTORS RE-APPOINTMENT OF AUDITOR ... | 1 | HKEx | ||
14.05. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
13.05. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS TO PRESENT UPDATED RESULTS FROM THE PHASE 2 STUDY OF IRPAGRATINIB IN COMBINATION WITH ... | 1 | HKEx | ||
06.05. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER ... | - | HKEx | ||
06.05. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 3 | HKEx | ||
29.04. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
28.04. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS FOUR LATE-BREAKING PRE-CLINICAL RESEARCH RESULTS ON ABSK112 (EGFR EXON20INS), ... | 2 | HKEx | ||
22.04. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
17.04. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - AMENDMENTS TO THE POST-IPO RSU SCHEME AND THE POST-IPO SHARE OPTION SCHEME | 1 | HKEx | ||
15.04. | ABBISKO-B (02256): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
BIONTECH | 95,35 | +0,05 % | BioNTech SE: BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt | BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard... ► Artikel lesen | |
VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
89BIO | 10,250 | +3,12 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
TREVI THERAPEUTICS | 7,060 | +4,75 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Patients saw a... ► Artikel lesen |